
@techreport{national_advisory_committee_on_immunization_naci_naci_2021,
	title = {{NACI} rapid response: {Recommended} use of {AstraZeneca} {COVID}-19 vaccine in younger adults},
	url = {https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/rapid-response-recommended-use-astrazeneca-covid-19-vaccine-younger-adults.html},
	urldate = {2021-04-03},
	institution = {National Advisory Committee on Immunization (NACI)},
	author = {{National Advisory Committee on Immunization (NACI)}},
	month = mar,
	year = {2021},
}

@techreport{paul-ehrlich-institut_pei_covid-19_2021,
	title = {{COVID}-19 {Vaccine} {AstraZeneca} - {Safety} assessment result: {The} vaccine is safe and effective in the fight against {COVID}-19},
	url = {https://www.pei.de/EN/newsroom/hp-news/2021/210319-covid-19-vaccine-astrazeneca-safety-assessment-result-vaccine-safe-and-effective.html},
	urldate = {2021-04-02},
	institution = {Federal Institute for Vaccines and Biomedicine},
	author = {{Paul-Ehrlich-Institut (PEI)}},
	month = mar,
	year = {2021},
}

@techreport{european_medicines_agency_covid-19_2021,
	title = {{COVID}-19 {Vaccine} {AstraZeneca}: benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets},
	url = {https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-benefits-still-outweigh-risks-despite-possible-link-rare-blood-clots},
	urldate = {2021-04-02},
	institution = {European Medicines Agency},
	author = {{European Medicines Agency}},
	month = mar,
	year = {2021},
}

@techreport{medicines__healthcare_products_regulatory_agency_coronavirus_2021,
	title = {Coronavirus vaccine - weekly summary of {Yellow} {Card} reporting},
	url = {https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting},
	urldate = {2021-04-03},
	author = {{Medicines \& Healthcare Products Regulatory Agency}},
	month = apr,
	year = {2021},
}
